• 1
    Lee W. Hepatitis B virus infection. N Engl J Med 1997; 337: 17331745.
  • 2
    McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976-1994. Am J Public Health 1999; 89: 1418.
  • 3
    Hepatitis B Foundation. “What is hepatitis B?” Statistics. Available at: Accessed April 20, 2007.
  • 4
    Poterucha JJ, Wiesner RH. Liver transplantation and hepatitis B. Ann Intern Med 1997; 126: 805807.
  • 5
    van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420424.
  • 6
    Liaw YF, Chu CM, Su IJ, Huang MY, Lin DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84: 216219.
  • 7
    Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 18391843.
  • 8
    Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 4758.
  • 9
    McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759768.
  • 10
    Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. HEPATOLOGY 2002; 35: 15221527.
  • 11
    Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg positive chronic hepatitis B. J Hepatol 2003; 39(suppl 1): S99S105.
  • 12
    Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 16601667.
  • 13
    Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168174.
  • 14
    Manno M, Camma C, Schepis F, Bassi F, Gelmini F, Miselli F, et al. Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756763.
  • 15
    Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 14221427.
  • 16
    Hui CK, Lau E, Monto A, Kim M, Luk JM, Poon RT, et al. Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantation. Am J Transplant 2006; 6: 16001608
  • 17
    Hui CK, Lau E, Wu H, Monto A, Kim M, Luk JM, et al. Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol 2006; 35: 182192.
  • 18
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a (40kD) (PEGASYS) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg positive chronic hepatitis B: results from a large, multinational study. N Engl J Med 2005; 352: 26822695.
  • 19
    Marcellin P, Lau G, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 12061217.
  • 20
    Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 6168.
  • 21
    Lau GK, Cooksley H, Ribeiro RM, Powers KA, Bowden S, Mommeja-Marin H, et al. Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg (+) chronic hepatitis B: efficacy and mechanisms of treatment response [Abstract]. HEPATOLOGY 2004; 40(Suppl 1): 666A.
  • 22
    Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528536.
  • 23
    Marcellin P, Mommeja-Marin H, Sacks SL, Lau GK, Sereni D, Bronowicki JP, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. HEPATOLOGY 2004; 40: 140148.
  • 24
    Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 893897.
  • 25
    Ishak KG, Baptista A, Bianchi L, Callea F, De Groote J, Gudak F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 26
    Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38: 257265.
  • 27
    Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42: 813819.
  • 28
    Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, et al. Hepatitis B reactivation after withdrawal of preemptive lamivudine in patients with hematological malignancy upon completion of cytotoxic chemotherapy. Gut 2005; 154: 15971603.
  • 29
    Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 5968.
  • 30
    Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 23242330
  • 31
    Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007; 45: 507539.
  • 32
    Hui CK, Lau GK. The natural history of chronic hepatitis B infection. In: ButiM, EstebanR. First edition. Barcelona: Grup 3, Viral Hepatitis 2006: 1423.
  • 33
    Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 6573.
  • 34
    Iloeje UH, Yang HI, Su J, Jen CL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678686.
  • 35
    Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003; 38: 511517.
  • 36
    Hui CK, Monto A, Belaye T, Lau E, Wright TL. Outcomes of interferon-α and ribavirin treatment for chronic hepatitis C patients with normal serum aminotransaminases. Gut 2003; 52: 16441648.
  • 37
    Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, et al. Serum hepatitis B virus HBV DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002; 36: 543546.
  • 38
    Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg clearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 10841089.
  • 39
    Hui CK, Lie A, Au WY, Leung YH, Ma SY, Cheung WW, et al. A long-term follow-up study on hepatitis B surface antigen positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005; 106: 464469.
  • 40
    Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 1818: 554559.
  • 41
    Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 14941498.
  • 42
    Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006; 55: 569578.
  • 43
    Braunstein H. Needle biopsy of the liver in cirrhosis. Arch Pathol 1956; 62: 8795.
  • 44
    Waldstein SS, Szanto PB. Accuracy of sampling by needle biopsy in diffuse liver disease. Arch Pathol 1950; 50: 326328.
  • 45
    Hubscher SG. Histological grading and staging in chronic hepatitis: clinical applications and problems. J Hepatol 1998; 10151022.
  • 46
    Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343350.
  • 47
    Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403408.